Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
Cash from Operating Activities
Glenmark Life Sciences Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
Cash from Operating Activities
₹3.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Operating Activities
₹72.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Operating Activities
₹37.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Operating Activities
₹121.9B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cash from Operating Activities
₹37.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash from Operating Activities
₹18.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Glenmark Life Sciences Ltd's Cash from Operating Activities?
Cash from Operating Activities
3.1B
INR
Based on the financial report for Mar 31, 2023, Glenmark Life Sciences Ltd's Cash from Operating Activities amounts to 3.1B INR.
What is Glenmark Life Sciences Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
17%
Over the last year, the Cash from Operating Activities growth was -48%. The average annual Cash from Operating Activities growth rates for Glenmark Life Sciences Ltd have been 17% over the past three years .